In the childhood cancer neuroblastoma (NB), the level of expression of the multidrug resistance-associated protein (MRP1) gene is strongly correlated with expression of the MYCN oncogene in primary NB tumors, suggesting that MRP1 may be a target for MYCN-mediated gene regulation. In this study, we show that MYCN induction in human NB cells results in increased MRP1 mRNA and protein levels, which in turn is accompanied by increased drug resistance and enhanced MRP1-mediated drug efflux. Furthermore, luciferase activity from MRP1 promoter/luciferase gene reporter constructs was significantly increased in NB cells with exogenous overexpression of MYCN, whereas activity was decreased in NB cells stably transfected with MYCN-antisense vectors. Decreased luciferase activity was observed with promoter constructs that lacked one or two E-box sequences or had E-box double point mutations, while a truncated MRP1 promoter lacking all three E-boxes exhibited only basal levels of activity. Specific electrophoretic mobility shifts of MRP1 E-box sequences were detected with nuclear extracts from NB cells with MYCN overexpression, and complex formation was inhibited with the addition of antibodies directed against MYCN or MYC. These findings indicate that by interacting with E-box elements within the promoter, MYCN can upregulate MRP1 expression and modulate drug resistance in NB.
Introduction
Neuroblastoma (NB) is a clinically heterogeneous pediatric neoplasm. A number of molecular and genetic abnormalities have been shown to correlate with response to therapy and outcome for patients with NB. One of the most powerful unfavorable prognostic factors is MYCN amplification, which occurs in approximately 20% of the NB tumors (Brodeur et al., 1984; Seeger et al., 1985) . MYCN is thought to critically contribute to the clinically aggressive behavior of highrisk MYCN-amplified NB tumors, and numerous laboratory studies support this hypothesis. The level of expression of MYCN has been shown to correlate directly with growth potential of NB cells in vitro as well as in vivo (Schweigerer et al., 1990; Negroni et al., 1991; Gross et al., 1994; Schmidt et al., 1994) . Furthermore, MYCN antisense experiments have shown that downregulation of MYCN is associated with decreased proliferation and an inhibition in anchorage-independent growth (Negroni et al., 1991; Schmidt et al., 1994) . A role for MYCN in NB pathogenesis is further supported by studies demonstrating NB tumor development in transgenic mice with targeted expression of MYCN (Weiss et al., 1997) .
The MYCN gene encodes a 60-63 kDa nuclear phosphoprotein that contains a basic helix-loop-helix/ leucine zipper (bHLH-LZ) motif (Ikegaki et al., 1986) . Like other members of the MYC family, MYCN is a transcriptional regulator that appears to play a critical role in cellular proliferation, differentiation, transformation, and apoptosis (Blackwell et al., 1990; Queva et al., 1998) . For MYCN to activate transcription, it must first dimerize to MAX, another bHLH-LZ protein (Blackwood and Eisenman, 1991) . The specificity of MYC transactivation is partly mediated through binding to a core E-box promoter sequence, CAT/CGTG, found in the promoter region of target genes. Although several genes have been identified that are upregulated by MYC proteins in vitro (Grandori and Eisenman, 1997; Boon et al., 2001) , the MYCN target genes critical for NB genesis and tumor progression have not yet been defined.
The multidrug resistance-associated protein (MRP1) gene encodes a 190 kDa membrane-bound glycoprotein that belongs to the superfamily of ATP-binding cassette (ABC) transmembrane transporters (Cole et al., 1992) . Similar to P-glycoprotein (Roninson, 1991) , MRP1 confers a multidrug-resistant phenotype in many tumor types including NB (Krishnamachary et al., 1994; Haber et al., 1999; Young et al., 1999) . In NB patients, poor prognosis has been shown to correlate with high-level expression of the MRP1 gene in primary tumors (Norris et al., 1996; Matsunaga et al., 1998; Bader et al., 1999) . Although gene amplification and transcriptional upregulation have been shown to be responsible for MRP1 overexpression in drug-resistant tumor cells, the regulatory mechanisms are not clearly understood and appear to be complex Center, 1994, 1996; Oshika et al., 1998; Wang and Beck, 1998; Sullivan et al., 2000) .
We and others have reported that high levels of MRP1 expression in NB tumors correlate with amplification and overexpression of the MYCN oncogene (Bordow et al., 1994; Norris et al., 1996 Norris et al., , 1997 Matsunaga et al., 1998; Bader et al., 1999) . The coordinate expression of the MRP1 and MYCN genes, coupled with the identification of three putative E-box motifs in the À1020 to À2008 bp promoter region, led us to hypothesize that MYCN may upregulate MRP1 expression and thereby render NB cells resistant to cytotoxic drugs (Norris et al., 1996 . In this study, we have further explored the relationship between MYCN and MRP1 expression using an MYCNinducible human NB cell line, and show that MYCN induction results in increased levels of MRP1 mRNA and protein, increased drug resistance, and enhanced MRP1-mediated drug efflux. Moreover, we found that MRP1 promoter activity correlated with MYCN expression in NB, and that all three E-box elements within the MRP1 promoter contributed to promoter activity. Electrophoretic gel mobility shift experiments performed with nuclear extracts from NB cells with high levels of exogenous MYCN expression and MRP1 E-box oligomer probes revealed specific complex formation. These data suggest that the transcriptional regulation of MRP1 by MYCN may enhance multidrug resistance in NB tumors.
Results

MRP1 is upregulated by inducible MYCN expression
We have previously reported that MRP1 expression correlates with amplification and overexpression of the MYCN oncogene in primary NB tumors (Bordow et al., 1994) . Here, the relationship between MYCN and MRP1 expression was further explored in NB cells stably transfected with the MYCN gene under the control of the rTET-inducible expression system (Tet21/ N) (Lutz et al., 1996) in which MYCN expression is induced on removal of tetracycline from the media. The level of MRP1 expression was first determined by reverse transcription (RT)-PCR, as we have previously described (Norris et al., 1996) , in the presence of tetracycline (Tet21/N þ ) or following its withdrawal (Tet21/NÀ). A highly significant increase in MRP1 expression (Po0.005) was observed in the cells induced to express MYCN (Tet21/NÀ) (mean PCR ratio ¼ 0.8470.030) by comparison with either the Tet21/N þ cells (mean PCR ratio ¼ 0.6170.028) or the parental SH-EP cells (mean PCR ratio ¼ 0.5770.017), with the latter two cell lines not differing significantly from each other. This increase was concomitant with the highly significant increase in MYCN expression in the Tet21/NÀ cells (mean PCR ratio ¼ 1.3170.052) compared to the Tet21/N þ cells (mean PCR ratio ¼ 0.7170.028). In order to assess whether MYCN induction following tetracycline withdrawal was associated with increased MRP1 protein expression, immunofluorescence analysis of the Tet21/ N þ and Tet21/NÀ cells was conducted using mAb MRPr1, which recognizes an internal epitope of human MRP1 (Young et al., 1999) . Consistent with the results of the RT-PCR analysis, fluorescence immunocytochemistry demonstrated clear membrane staining in the Tet21/NÀ cells, while staining was virtually absent in Tet21/N þ cells (Figure 1 ).
MRP1-mediated drug resistance is enhanced following MYCN induction
To determine the influence of this increased MRP1 expression on drug response, the Tet21/NÀ cells were compared with the Tet21/N þ and SH-EP cells in terms of their response to either the well-characterized MRP1 substrate, vincristine, or to the non-MRP1 substrate, cisplatin. 
MYCN activates the MRP1 promoter
To study the transcriptional regulation of MRP1 expression in NB cells, initial transfection experiments were performed with the full-length 2.2 kb MRP1 luciferase/promoter reporter construct (MRPFL) which contains several transcription factor-binding sites including three putative E-box elements (E-box 1 at À2140, E-box 2 at À1714, and E-box 3 at À1033) (Zhu and Center, 1994) (Figure 3 ). The effects of increased exogenous MYCN expression on MRP1 promoter activity were examined in SH-EP NB cells stably transfected with an expression vector containing fulllength MYCN cDNA driven by the constitutive CMV promoter (SH-EP/MYCN) (Haber et al., 1999) , and in the MYCN-inducible cell line Tet21/N. Additional luciferase assays were performed with three MYCN antisense NB clones (NBAS-1, NBAS-3, and NBAS-5) Figure 3 Schematic cartoon of the MRP1 promoter/luciferase constructs generated for use in this study. The positions of the three putative E-box elements, the E-box deletions, and the point mutations are indicated MRP1 regulation in neuroblastoma CF Manohar et al that constitutively express high levels of a 1.2 kb antisense MYCN cDNA and have downregulated MYCN protein levels in comparison to a control cell line transfected with empty vector (NBV-1) (Schmidt et al., 1994) . MRP1 promoter activity paralleled the level of MYCN expression in all three experimental models. In SH-EP/MYCN cells that have constitutive MYCN expression, MRP1 activity was increased 60% compared to controls (SH-EP/CMV) (luciferase activity7s.e.; 10072% vs 3876%, respectively; Po0.001) (Figure 4a ). In addition, MRP1 promoter activity increased by 20% in the Tet21/N cells with MYCN induction (luciferase activity7s.e.; Tet21/NÀ: 10079% vs Tet21/N þ : 7973%; Po0.006) (Figure 4b ). In contrast, a 50-80% decrease in MRP1 promoter activity was observed in the MYCN antisense clones (luciferase activity7s.e.; NBV-1: 10079%; NBAS-1: 5272%; NBAS-3: 1870.3%; NBAS-5: 1870.9%; Po0.05) (Figure 4c ). These experiments were performed at least three times, and the results shown are representative for each NB cell system.
Putative E-box motifs in the MRP1 promoter function as positive cis-acting elements in NB To investigate the role that the putative E-box elements play in the regulation of MRP1 expression in NB cells, reporter constructs were generated with one, two, or three E-box deletions (MRPdel-2085 , MRPdel-1527 , MRPdel-1321 , and MRPdel-1020 and transiently transfected into SH-EP/MYCN and Tet21/N cells. Additional experiments were performed with MRP1 promoter reporter constructs (MRPmutEB1, MRPmut EB2, MRPmutEB3, and MRPmutEB123) that contained double or triple point mutations in the putative E-box elements ( Figure 3 ). Similar patterns of MRP1 promoter activation were seen in both cell line models (Figure 5a and b) .
The major MRP1 promoter activity was determined to reside in the region containing E-box 3, between bp À1020 and À1321. Basal levels of promoter activity were observed in experiments performed with MRPdel-1020, a construct that lacked all three E-box elements. Luciferase assays performed with promoter reporter constructs that contained the putative E-box 3 motif (MRPdel-1321 and MRPdel-1527) exhibited a 60-80% increase in activity compared to that seen with MRPdel-1020 (Figure 5a and b) (luciferase activity7s.e. in Tet21/ NÀ; MRPdel-1321: 6370.7%, MRPdel-1527: 7976%, MRPdel-1020: 675%, Po0.001: luciferase activity in SH-EP/MYCN; MRPdel-1321: 5672%, MRPdel-1527: 6973%, MRPdel-1020: 1070.4%, Po0.01). A modest further increase in activity was seen with the recombinant promoter construct that contained two E-box elements (MRPdel-2085: 8072%) in the SH-EP/ MYCN cells, whereas no significant change was seen in experiments performed with the Tet21/NÀ cells (data not shown). The highest levels of MRP1 promoter activity were seen with the full-length promoter reporter construct (MRPFL), which contains all three E-box sequences. An MRP1 promoter reporter construct containing a mutated E-box 3 (MRPmutEB3) resulted in a 30% decrease in MRP1 activity compared to MRPFL (Po0.001) (Figure 5a and b) . Mutation of Ebox 1 or E-box 2 resulted in a similar although smaller decrease in MRP1 activity (data not shown). However, the level of luciferase activity detected in experiments performed with a reporter construct with mutations of all three E-box sequences (MRPmut EB123) was essentially the same as that observed with the single mutated E-box 3, indicating that there were no cumulative or synergistic effects. 
MYCN protein binds to E-box elements in the MRP1 promoter
Electrophoretic mobility shift assays (EMSAs) were performed to determine whether MYCN was capable of binding to the E-box elements within the MRP1 promoter sequence. Since E-box 3 was determined to reside in the region of the MRP1 promoter associated with major promoter activity, studies were performed with NB nuclear extracts and end-labeled E-box 3 MRP1 probe. As shown in Figure 6a , a shifted band of strong intensity was seen in experiments performed with nuclear extracts from the MYCN-overexpressing SH-EP/MYCN cells, whereas this complex was not detected with the control SH-EP/CMV extracts. Furthermore, antibodies directed against MYCN and MYC completely inhibited the complex formation. The nature of the lower band in the lane with MYC antibody is unknown. However, based on its mobility, we speculate that it may be a single-stranded E-box oligomer-MYC complex.
We were not able to detect a supershift of the complex with antibodies, suggesting that the MYCN and MYC antibodies interfere with the formation of the MYCfamily member/MAX/promoter complex, but do not bind to the intact protein/DNA adduct. MAX, ID2, and SP1 antibodies had little effect on complex formation. Experiments performed with probes for E-box 1 and E-box 2 also revealed specific protein-DNA complexes, and complex formation was disrupted with the addition of anti-MYC or anti-MYCN antibodies (data not shown).
Competition experiments using cold wild-type and mutated E-box probes were performed to establish the specificity of the E-box nuclear protein binding. cells with deletion mutants of the MRP1 promoter indicate that major promoter activity resides in the upstream À1020 to À1321 bp region. A truncated promoter that lacked all three putative E-box elements (MRPdel-1020) had basal levels of activity. MRP1 promoter activity was restored 60-80% with the addition of bp À1020 to À1321 or bp À1020 to À1527 (MRPdel-1321 and MRPdel-1527). MRPdel-1321 and MRPdel-1527 contain the putative E-box 3 element. On introduction of double or triple point mutations to disrupt the E-box motifs, promoter activity was downregulated by 30%. *Po0.05 for all comparisons shown Representative EMSA performed in the presence of unlabeled wild-type (EB3) or mutant E-box 3 (MB3) probe. A 20-, 50-, and 100-fold excess of cold E-box 3-oligomer inhibited the E-box 3 complex formation, whereas the addition of mutated E-box 3 did not. No significant inhibition was observed with 100-fold excess of the negative control AP1
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Pronounced inhibition of complex formation was observed with excess cold wild-type E-box sequence, whereas mutated sequences had minimal effects. A representative EMSA assay, wherein E-box 3 probe was incubated with NB nuclear extracts in the presence of 10-, 20-, 50-, and 100-fold excess of cold oligonucleotides, is shown in Figure 6b . This inhibition is abrogated with a wild-type E-box 3 probe. No inhibition of complex formation was seen with mutated E-box 3 probe or the negative control AP1 probe. Similar patterns of E-box specificity were observed in competition assays performed with cold wild-type, mutated E-box 1 or E-box 2 oligonucleotides (data not shown).
Discussion
Although many high-risk NBs initially respond to the first cycles of intensive chemotherapy, they frequently become refractory to treatment as the disease progresses. MYCN clearly contributes to the drug-resistant phenotype of NB, as amplification of this oncogene is strongly associated with rapid tumor progression and poor prognosis (Brodeur et al., 1984; Seeger et al., 1985) . A strong association between MYCN amplification and expression and enhanced levels of the drugresistance gene MRP1 has been demonstrated in NB tumors (Bordow et al., 1994; Norris et al., 1996 Norris et al., , 1997 Matsunaga et al., 1998; Bader et al., 1999; Haber et al., 1999) , suggesting that this drug efflux protein plays a key role in rendering NB cells resistant to cytotoxic therapy. In this study, we show that MRP1 expression paralleled MYCN expression in an MYCN-inducible NB cell line, and that cells induced to express MYCN and MRP1 exhibited increased drug resistance associated with enhanced MRP1-mediated drug efflux. Furthermore, luciferase assays, performed with a series of MRP1 promoter/reporter constructs, demonstrated that MRP1 promoter activity directly correlated with MYCN expression. The major positive cis-acting elements were found to reside between promoter sequence À1020 and À1321 bp upstream of the start site, and a putative E-box element (E-box 3) is located in this region of the promoter (Zhu and Wang and Beck, 1998; Kurz et al., 2001) . Two additional putative E-box motifs reside upstream of bp À1321, and promoter activity was further enhanced with promoter/reporter constructs containing two or all three of the putative E-box motifs. Mutation of each E-box sequence resulted in a consistent decrease in MRP1 promoter function, although significant luciferase activity was retained in these experiments, indicating that additional positive cis-acting elements reside in this region of the promoter that contribute to the regulation of the MRP1 gene in NB.
To test the hypothesis that MYCN mediates the regulation of the MRP1 gene, EMSAs were performed with NB nuclear proteins and probes corresponding to the three putative E-box elements in the MRP1 promoter. Quantitative increases in the levels of DNA-protein complexes were clearly evident upon overexpression of MYCN, and competition assays demonstrated the specificity of the complexes. Furthermore, antibodies that recognize MYCN or MYC were capable of effectively disrupting the formation of the Ebox nuclear protein binding complexes, although a supershift of the complex was not observed. A similar inhibition of complex formation with anti-MYC antibodies has recently been reported in EMSAs performed with an E-box probe from another putative MYCN target, the MCM7 gene (Shohet et al., 2002) . Interestingly, these authors (Shohet et al., 2002) as well as other investigators (Weihua et al., 1997) have also failed to demonstrate a supershift with anti-MYC antibodies, suggesting that the antibodies interfere with the formation of the promoter complex.
Zhu and Center first isolated the 5 0 -flanking sequence of the MPR1 gene from a genomic library prepared from HL60/ADR cells and reported full promoter activity with a 2.2 kb MRP1 promoter sequence (Zhu and Center, 1994) . In contrast to our results, deletion mutants demonstrated that the major MRP1 promoter region was located in the 194-nucleotide fragment extending from À91 to þ 103 bp in the MRP1 genome Center, 1994, 1996) . Promoter activity was lost with promoter sequence À411 to þ 103 bp, suggesting the presence of a strong negative cis-acting element in this region of the promoter. Different positive and negative cis-acting MRP1 promoter elements were identified in promoter-reporter studies performed by Wang and Beck (1998) . Their studies indicated that positive cis-acting elements were located between À91 and À411 bp of the MRP1 promoter, whereas negative elements were present between À1123 and À2008 bp of the promoter (Wang and Beck, 1998) . Although the reasons for the discrepant results are not clear, transacting factors appear to play an important role in regulating MRP1 promoter activity and may confer cell specificity. Interestingly, wild-type p53 has been shown to substantially inhibit MRP1 promoter activity (Wang and Beck, 1998) , and unlike most types of cancer, wildtype p53 is commonly detected in NB tumors at diagnosis (Vogan et al., 1993) . Thus, the unique finding that only basal levels of MRP1 activity were detected in NB cells with the MRPdel-1020 reporter construct may be consequent to the presence of wild-type p53 in SH-EP cells (Tweddle et al., 2001) .
Although available evidence strongly suggests that MRP1 is critically associated with the drug-resistant behavior of primary NB (Norris et al., 1996; Matsunaga et al., 1998; Bader et al., 1999) , this drug efflux pump does not appear to mediate resistance to either alkylating agents or platinum compounds (Gottesman et al., 2002) . Members of both these classes of compounds, such as cisplatin and cyclophosphamide, are commonly used in the treatment of NB (Brodeur and Maris, 2001) . Thus, despite the high levels of MRP1 observed in many aggressive NBs at diagnosis, the use of these non-MRP1 substrate drugs may explain why the majority of NB do initially respond to chemotherapy. Nevertheless, over half of these previously responsive tumors will eventually relapse with chemoresistant disease, suggesting the development of additional drug-resistance mechanisms. Evidence is accumulating that inactivation of p53 frequently occurs at relapse (Keshelava et al., 2001; Tweddle et al., 2003) . Thus, abnormalities of the p53 pathway may be linked to the drug resistance that is observed as the disease progresses.
Clinical drug resistance in NB, as in other cancers, is believed to be a multifactorial process involving the action of multiple gene pathways. In this regard, a number of genes have been identified as being associated with multidrug resistance in this disease, and the underlying mechanisms involved include alterations in drug transport, detoxification pathways, DNA repair or apoptosis, and either oncogene activation or loss of tumor suppressor genes (reviewed in Haber and Kavallaris, 2000) . In an experimental in vitro metastatic NB model, Blanc et al. (2003) recently reported that MYCN directly regulated MDR1 gene expression. In this model, the degree of drug resistance directly correlated with the expression levels of MYCN and Pglycoprotein, the multidrug resistance transporter encoded by the MDR1 gene. However, in clinical NB studies, conflicting reports exist regarding the prognostic value of MDR1 expression (Goldstein et al., 1990; Chan et al., 1991; Norris et al., 1996) . Although P-glycoprotein expression was reported to be a predictor of outcome of therapy for NB patients in some studies (Goldstein et al., 1990; Chan et al., 1991) , other series have failed to show any correlation (Favrot et al., 1991; Norris et al., 1996) . In one study, high levels of MDR1 expression were found to be predictive of outcome only in older children with NB tumors that lacked MYCN amplification . Furthermore, in contrast to MRP1, the level of expression of MDR1 is lower in tumors with MYCN amplification compared to those without amplification (Nakagawara et al., 1990; Favrot et al., 1991; Norris et al., 1996) . Thus, the contribution, if any, of MDR1 expression to the drugresistant phenotype of MYCN-amplified NB tumors remains unclear.
The results of our study support a major role for MRP1 in the overall drug-resistant phenotype of NB tumors with MYCN amplification and high levels of MYCN expression. MYCN contributes to the regulation of the MRP1 gene by interacting with a putative Ebox element in addition to other cis-acting factors in the MRP1 promoter, and the consequent enhanced levels of MRP1 expression result in increased drug resistance. The established association between MYCN amplification and poor outcome may therefore be due, at least in part, to the protection of NB cells against cytotoxic chemotherapy provided by high levels of MRP1. Recent studies suggest that MRP1 may also influence the capacity of NB cells to undergo spontaneous regression in vivo by blocking cell differentiation and apoptosis (Peaston et al., 2001; Kuss et al., 2002) . Thus, in addition to mediating multidrug resistance, the transcriptional activation of MRP1 by MYCN may contribute to the clinically aggressive nature of MYCN-amplified NB tumors by modulating NB growth. Taken together, the results indicate that strategies aimed at inhibiting MYCN and/or MRP1 may have therapeutic potential in children with aggressive MYCN-amplified neuroblastoma.
Materials and methods
NB cell culture
NB clones transfected with antisense (NBAS-1, -3, and -5), sense MYCN (SH-EP/MYCN) cDNA, or control, empty vectors (NBV-1 and SH-EP/CMV) were established in our laboratory and have previously been described (Schmidt et al., 1994; Haber et al., 1999) . The cells were cultured in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Invitrogen), Lglutamine (2 mM) (Invitrogen), and antibiotics. The Tet21/N cells, which are derived from the SH-EP NB cell line, express MYCN under the control of tetracycline (tet-off) (a kind gift from Dr Manfred Schwab, German Cancer Research Center, Heidelberg, Germany) (Lutz et al., 1996) . The Tet21/N cells were grown in RPMI 1640 augmented with L-glutamine (2 mM), antibiotics, and tetracycline-free FBS (Clontech, Palo Alto, CA, USA) (Tet21/NÀ) or serum plus 2 mg/ml of tetracycline (Sigma, St Louis, MO, USA) (Tet21/N þ ) for at least 1 week before each experiment. The media containing tetracycline were changed daily prior to and during the experiments.
RT-PCR
The synthesis of cDNA using Moloney murine leukemia virus reverse transcriptase and random hexanucleotide primers, and the RT-PCR assay have been described previously (Bordow et al., 1994; Norris et al., 1996) . A cDNA equivalent of approximately 50 ng was amplified for 30 cycles using primers to either the MYCN or MRP1 target genes together with primers for a control gene (b 2 microglobulin) in the same tube. Primer pairs, described elsewhere (Bordow et al., 1994; Norris et al., 1996) , were selected on the basis that they spanned an intron-exon boundary, and were tested to ensure that they did not amplify genomic DNA. Following polyacrylamide gel electrophoresis, the level of expression of either MYCN or MRP1 was densitometrically determined using the Gel Doc 1000 Gel Documentation System (BioRad Laboratories, Sydney, Australia) and expressed relative to the level of the control b 2 -microglobulin gene expression. Experiments were performed in triplicate.
Fluorescence immunocytochemistry
Cells (2 Â 10 4 ) were centrifuged onto glass slides at 800 r.p.m. for 10 min (Cytospin 3; Shandon, Pittsburgh, PA, USA) and then fixed for 10 min in ice-cold acetone. Air-dried slides were rinsed in PBS and then blocked in 20% normal goat serum/ PBS for 1 h. Slides were incubated for 1 h at room temperature with a monoclonal anti-human MRP1 antibody (MRPr1 (1 : 20); Alexis Biochemicals (San Diego, CA, USA), washed three times in PBS for 5 min, and then incubated for 1 h with a Cy3-conjugated goat anti-rat antibody (1 : 1000; Amersham, UK) at room temperature. Following three washes in PBS for 5 min, slides were counterstained with DAPI II (Vysis Inc., Downers Grove, IL, USA) and visualized by fluorescence microscopy, using a Zeiss Axioplan 2 microscope. Images were captured using a Sensican CCD camera. To ensure accurate comparisons between experiments, all cells were imaged using the same exposure times.
Cytotoxicity assays
Vincristine and cisplatin were purchased from Sigma (St Louis, MO, USA). Difloxacin was kindly provided by Abbott Laboratories (Abbott Park, IL, USA), while MK571 was purchased from Alexis Biochemicals. Cells were seeded in 96-well plates and cell growth inhibition was determined after 72 h of continuous exposure in vitro to various concentrations of cytotoxic drugs in either the presence or absence of difloxacin (100 mM) or MK571 (50 mM), using a microtiter-based assay with the Alamar Bluet reagent (Astral Scientific, Sydney, Australia). Determination of ID 50 values and statistical analysis were performed as described previously (Haber et al., 1989) . The statistical significance between ID 50 values from different cell lines was assessed by t-tests, using two-sided P-values.
Drug accumulation studies
The intracellular accumulation of vincristine was determined by adding [ 3 H]vincristine in fresh growth medium, in either the presence or absence of tetracycline as indicated, to cells in 12-well plates, and monitoring drug uptake at specific time points over 4 h. The mean incorporation was determined for duplicate wells, to which [ 3 H]vincristine (7.1 Ci/mmol; final concentration, 14 nM) was added. Cultures were incubated at 371C, and incubations were terminated at the end of specified time intervals by washing cell monolayers three times in rapid succession with ice-cold PBS, and lysing with 0.2 M NaOH (500 ml) for 1 h at 701C. The lysate was then neutralized with 0.2 M HCl (500 ml), after which an aliquot was removed to measure protein content. Samples were then counted following addition of scintillant (Ultima Gold, Packard, Meriden, CT, USA; 2 ml). Results were expressed as pmol of vincristine per mg protein. To study the effect of MRP1 inhibition on vincristine uptake, cells were incubated with [ 3 H]vincristine for 4 h in the absence or presence of MK571 (50 mM). Samples were then washed, lysed, neutralized, and counted as described above. The statistical significance between the intracellular accumulation of vincristine in the various cell lines was assessed by t-test, using two-sided Pvalues.
Construction of MRP1 promoter-luciferase plasmids
The full-length 2.2 kb (MRPFL) and the 1.02 kb deletion (MRPdel-1020) MRP1 luciferase reporter constructs were kind gifts of Dr Roger Deeley (Cancer Research Laboratory, Queen's University, Kingston, Ontario, Canada). MRPFL contains three putative E-box motifs, and all three are deleted in the MRPdel-1020 luciferase reporter construct. Fragments with one or two E-box deletions were generated with the restriction endonucleases BsaBI (À2085), BalI (À1527) and NsiI (À1321). The fragments were then digested with HindIII and recloned into pGL3 (Promega, Madison, WI, USA) to obtain MRPdel-2085, MRPdel-1527, and MRPdel-1321, respectively. The putative E-box motifs in the 2.2 kb insert were disrupted by double or triple point mutations using the Altered Sites II in vitro Mutagenesis System (Promega) to create MRPmutEB1, MRPmutEB2, MRPmutEB3, and MRPmutEB123. The following wild-type and mutant oligonucleotides were used to introduce mutations in the putative E-boxes. Sequence identity of the full-length and mutated MRP1 recombinant vectors was ). Transfections were performed in six-well dishes using Superfect Reagent (Qiagen, Valencia, CA, USA) according to the manufacturer's directions using 2 mg/well recombinant MRP1 luciferase reporter constructs and 1 mg/well CMV b-gal reporter plasmid (MacGregor and Caskey, 1989) . Luciferase activity was measured 36 h post-transfection using the Promega Luciferase Assay System and measured on an LB 96 luminometer (EG & G Berthold MicroLumat, Gaithersburg, MD, USA). To normalize for transfection efficiency, lysates were also analysed for b-galactosidase activity using the Promega b-Galactosidase Enzyme Assay System. All experiments were repeated at least three times, and the Student's t-test was used to compare statistically the luciferase activity in the different cell lines.
EMSAs
Nuclear and cytoplasmic extraction reagents (Pierce, Rockford, IL, USA) were utilized to prepare nuclear extracts from logarithmically growing cell cultures according to Dignam's protocol with some modifications (Dignam, 1990) . Cells were spun down, washed with 1 Â PBS and suspended in hypotonic buffer. The swollen cells were homogenized and nuclei pelleted. After removing the cytoplasmic fraction, the nuclei were suspended in a low-salt buffer (10 mM HEPES, pH 7.9 at 41C, 25% glycerol, 1.5 mM MgCl 2 , 10 mM KCl, 0.2 mM PMSF, 0.5 mM DTT) and protease inhibitor mix. Soluble proteins were released from the nuclei without lysing with the gentle addition of high-salt buffer (20 mM HEPES, pH 7.9 at 41C, 25% glycerol, 1.5 mM MgCl 2 , 800 mM KCl, 0.2 mM PMSF, 0.5 mM DTT). Nuclei were centrifugally removed and nuclear extracts were dialysed into a moderate salt solution. Any precipitated proteins were removed by centrifugation. Extracts were aliquoted and frozen in liquid nitrogen and stored at À801C until use. In some experiments, the services of Geneka Inc. (Montreal, Canada) were used to prepare nuclear extracts. The BioRad Protein Assay Reagent (BioRad, Hercules, CA, USA) was utilized to quantitate the nuclear extracts following the manufacturer's protocol. The oligonucleotide probes were generated by annealing commercially prepared sense and complement sequences followed by end-labeling with [g-32 P]ATP and T4 polynucleotide kinase. The following (25-bp) MRP1 probes containing wild-type or mutated E-box sequences were used in the EMSA studies: Each EMSA was performed with nuclear extracts corresponding to 12 mg of protein after quantification by the Bradford assay (Bradford, 1976) . The nuclear extracts were incubated with Poly(dI.dC).poly(dI.dC) (Sigma) in 20 ml of 20 mM HEPES, pH 7.5, 80 mM KCl, 1 mM DTT, 1% NP40, 50% glycerol, and protease inhibitors at room temperature for 10 min. E-box-labeled oligonucleotide probe (as shown above) (20 Â 10 3 c.p.m.) was added to the mix and further incubated for 30 min at RT. Dye (0.1% bromophenol blue in 50% glycerol) was added to the reaction mix and loaded on a 4% polyacrylamide/0.5 Â TBE gel. Gels were prerun at 170 V for 30 min. Gels were dried and exposed to Xray film overnight at À701C. Competition inhibition assays were carried out by using cold competing oligos at varying concentrations prior to the addition of labeled probe. Antibodies directed against MYCN, MYC, MAX, ID2, and SP1 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) were added to nuclear extracts prior to the addition of labeled probes as well.
